The chief executive of Germany's BioNTech SE, Ugur Sahin, said the biggest challenge facing it and partner Pfizer Inc now that their COVID-19 vaccine is authorized for use in the United States will be to scale up manufacturing to meet huge demand.
BioNTech CEO looks for more vaccine production
You might like
Related news coverage